<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite the advances and new drug discoveries, the best drug in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mcrc) is <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>This drug is the backbone of FOLFOX and FOLFIRI which are the standard first line cytotoxic regimens in the metastatic setting </plain></SENT>
<SENT sid="2" pm="."><plain>The efficacies of these two regimens are equivalent, and the selection of one over the other is largely based on the side effect profile </plain></SENT>
<SENT sid="3" pm="."><plain>Bevacizumab is commonly added to each of these regimes in the first line setting </plain></SENT>
<SENT sid="4" pm="."><plain>When a patient develops progression of disease on FOLFOX, then treatment with either single agent irinotecan, or FOLFIRI is a typical approach </plain></SENT>
<SENT sid="5" pm="."><plain>If FOLFIRI-BEV is used in first line, the FOLFOX is typically given in second line </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> have their <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tested for the KRAS mutation in exon 2 </plain></SENT>
<SENT sid="7" pm="."><plain>If the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> is KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> then either cetuximab or panitumumab, with or without continued irinotecan, may be used </plain></SENT>
<SENT sid="8" pm="."><plain>In patients whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are symptomatic, and so requiring a rapid response, cetuximab or panitumumab may be incorporated into second line therapy instead of third line </plain></SENT>
<SENT sid="9" pm="."><plain>There are no data supporting the use of cetuximab after progression on panitumumab or vice versa and use of one of these agents after failure on the other is not appropriate </plain></SENT>
<SENT sid="10" pm="."><plain>Upon progression on the standard chemotherapies outlined above appropriate patients may be offered participation in a clinical trial </plain></SENT>
<SENT sid="11" pm="."><plain>For patients whose <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> are KRAS mutant a clinical trial should be considered upon progression on <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and irinotecan-based regimens </plain></SENT>
<SENT sid="12" pm="."><plain>New agents and combinations of targeted therapies described below offer promising therapies for patients with both KRAS <z:mp ids='MP_0002169'>wild type</z:mp> and mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>As our molecular knowledge of mcrc advances future therapies will likely tailor an individualized approach based on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specific molecular markers </plain></SENT>
</text></document>